A large study confirmed that users of GLP-1 drugs who lost meaningful weight had substantially reduced risks of major obesity-related conditions.
Sleep apnea risk declined sharply among participants with significant weight loss on the medications.
Kidney disease risk also fell compared with groups without comparable weight reduction.
GLP-1 drugs mimic hormones that regulate appetite and blood sugar.
Obesity increases pressure on organs and contributes to breathing interruptions during sleep.
Researchers tracked outcomes across a broad patient population over an extended follow-up period.
Weight loss appeared to mediate much of the benefit rather than drug effects independent of pounds shed.
Sleep apnea affects millions and is closely tied to excess body weight.
Kidney disease shares metabolic risk factors with obesity and diabetes.
The findings support using GLP-1 therapies where weight reduction is achieved and sustained.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/